GlassScriptPhysician profile
Deborah J Reeder
NPI 1881662708
$540.38
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.16 · 2022: $38.32 · 2023: $236 · 2024: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $434.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $84.70 | 2022-2024 | Tyrvaya |
| Bausch & Lomb Americas INC. | $73.32 | 2022-2024 | Vyzulta, Miebo |
| Abbvie INC. | $61.99 | 2023-2024 | |
| Tarsus Pharmaceuticals, INC. | $51.02 | 2024 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $50.19 | 2024 | |
| Novartis Pharmaceuticals Corporation | $41.53 | 2023 | |
| Rayner Intraocular Lenses Limited | $38.38 | 2023 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Tearlab Corp | $27.32 | 2023 | Tearlab Osmolarity System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $25.31 | 2019 | |
| Alcon Vision LLC | $23.53 | 2023 | Rocklatan |
| Dompe US, INC. | $21.24 | 2024 | Oxervate |
| Allergan, INC. | $14.59 | 2019 | |
| Omeros Corporation | $13.76 | 2019 | |
| Shire North American Group INC | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Reeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.